Buvidal® weekly and monthly – now available to patients in Switzerland

In January 2025, Buvidal^® (buprenorphine) prolonged-release solution for subcutaneous injection, was launched and made accessible to patients with opioid dependence in Switzerland. The product offers a flexible treatment approach with both weekly and monthly formulations, tailored to meet the diverse needs of individuals battling opioid dependence.  

Opioid dependence is a severe, chronic, and relapsing disease that profoundly affects both individuals and society, presenting a major challenge for healthcare systems worldwide.^1,2 In Switzerland, opioid dependence has been on the rise with cases of opioid overdoses nearly tripling over the last two decades, underscoring the urgent need for effective treatment solutions.³

“With Buvidal, we offer an advanced and patient-centered treatment that significantly eases the daily lives of people with opioid dependence. The option of weekly or monthly administration instead of daily medication greatly both relieves the lives of patients and ease the burden on the healthcare providers, has shown to increase patient treatment satisfaction, and helps disrupt daily addiction rituals”, says Jens Gabbert, General Manager DACH at Camurus. “We are very pleased to contribute to the destigmatization of opioid dependence and to improving the quality of life for those affected with this new form of therapy.”

Buvidal is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment and is intended for use in adults and adolescents aged 16 years or over.⁴ Since its first launch in 2019, the product is today available in more than 20 countries in Europe, Australia, and the US. In the US, the product is marketed under the brand name Brixadi by Camurus’ licensee Braeburn.

For more information on Buvidal, see: https://buvidal.com/.

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

References

1. Volkow ND. Medications for Opioid Use Disorder: Bridging the Gap in Care. N Engl J Med 2017; 377(4): 391–394.
2. Degenhardt L., et al. Addiction. 2014; 109(8): 1320-1333.
3. Swiss Info, "Opioid abuse on the rise in Switzerland," June 28, 2022, Opioid abuse on the rise in Switzerland - SWI swissinfo.ch.  
4. Buvidal^® Product Information Switzerland, March 2024.